Please use this identifier to cite or link to this item:
|Title:||The regulatory use of the Local Lymph Node Assay for the notification of new chemicals in Europe.|
|Authors:||ANGERS ALEXANDRE; TOSTI LUCA; CASATI Silvia|
|Citation:||REGULATORY TOXICOLOGY AND PHARMACOLOGY vol. 60 no. 3 p. 300-307|
|Publisher:||ACADEMIC PRESS INC ELSEVIER SCIENCE|
|Type:||Articles in periodicals and books|
|Abstract:||We have monitored the regulatory use of the LLNA for chemicals registration from the time of its adoption as stand alone method at the OECD to 2008. For this, we screened the New Chemicals Database (NCD) which was managed during this period by the former European Chemicals Bureau (ECB) at the European Commission Joint Research Centre (JRC). The NCD comprises chemicals notified after 1981, where registered data have been derived according to regulatory standards, including GLP and predominantly according to official test methods. The database was searched to extract records for which the information for skin sensitisation labelling was based on results derived with the LLNA. The details of these records were extracted and pooled, for a total of 545 entries, and evaluated with regards to the extent of use of the LLNA over time and countries, as well as analysing the information derived on critical aspects of the procedure e.g strain and amount of animals used, lymph node processing, solvent and doses selected, stimulation indices, and assessing their level of compliance to the OECD 429. Additional information on labelling was extracted, and its significance for the potential of the widespread use of the reduced version of the LLNA is discussed on the text.|
|JRC Institute:||Institute for Health and Consumer Protection|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.